- empe
- 2026-11-11
- No Comments
Resources
Ending TB means ending our assumptions: a view from diagnostics
Commentary on Rattan A. and Arora V.K., “Ending tuberculosis requires ending assumptions”, Indian Journal of Tuberculosis (editorial, in press, 2026). https://doi.org/10.1016/j.ijtb.2026.10.003
India’s target of ending tuberculosis by 2025 has now passed. In a new editorial in the Indian Journal of Tuberculosis, Prof. Ashok Rattan and Prof. V.K. Arora don’t go back over the target. They ask a harder question: if the programme had been carried out flawlessly, would it have worked? Their answer is uncomfortable. The programme’s design rests on a model of how TB spreads that genomic epidemiology, prevalence surveys and controlled trials have steadily taken apart.
At EMPE Diagnostics we think this editorial should be read widely, especially by anyone who runs a laboratory, a testing programme or a TB budget.
Delayed diagnosis prolongs transmission
The authors’ central point is simple. A person with undiagnosed pulmonary TB may infect many others, roughly eight to twelve, during about a year of illness before effective treatment begins. They recall the landmark Indian home-versus-sanatorium trial, which found that household contacts of patients treated at home had no meaningfully higher infection rate than contacts of patients sent away to a sanatorium. In other words, once treatment starts, transmission falls quickly. A central gap is delayed diagnosis, and closing it must go hand in hand with prompt access to effective treatment.
Three assumptions worth retiring
The editorial names three habits in clinical practice that the evidence no longer supports:
1. Smear or culture conversion as a measure of infectiousness. Infectiousness drops within days of effective therapy, long before sputum converts. Isolating patients on the basis of a two-month smear answers the wrong question, and the patient pays for it in stigma, lost wages and lost schooling.
2.The symptom screen. India’s National TB Prevalence Survey found that about half of people with TB reported no symptoms, and that many with symptoms had not sought care. Asymptomatic patients are estimated to drive about half of all transmission. Asking about two weeks of cough leaves half the epidemic out of view.
3.The household as the main place of danger. Genomic studies show that much transmission happens through casual contact in the community, including shared outpatient waiting areas, rather than through close household contact. Airborne infection control at clinics and specimen collection points is an intervention in its own right.
The cascade is where people are lost
The authors also look at the care cascade. More than a quarter of people with prevalent TB never reach a diagnostic facility. More are lost at the testing stage, mostly people with smear-negative or drug-resistant disease that microscopy cannot detect. A substantial share of those diagnosed never start treatment, sometimes for reasons as basic as an unreadable phone number. The editorial also warns that scaling up active case finding without matching retention efforts risks turning detection into a notification statistic rather than a cure.
What this means for diagnostics
We see three practical lessons in this editorial for those of us working in TB testing:
- Test beyond symptoms. If half of people with TB have no symptoms, then screening has to be built on sensitive molecular testing rather than on symptom questionnaires and smear microscopy.
- Detect resistance early, and keep pace with treatment. Drug-resistant TB is disproportionately lost at the testing stage. As shorter all-oral regimens such as BPaLM become standard, testing has to cover the drugs patients actually receive, not only rifampicin.
- Bring molecular testing to district level. Every extra visit, referral or day of waiting is another chance to lose someone. Robust tests that run in district and regional laboratories, on the instruments they already own, shorten the interval between first contact and effective treatment.
This is the thinking behind our portfolio, which is built on our proprietary PLi‑RCA technology (padlock probe-linked rolling circle amplification). mfloDx™ MDR‑TB, our CDSCO-approved test, detects TB and resistance to both rifampicin and isoniazid in a single test, with results read by eye. Our new CircuLOK range brings the same chemistry to the real‑time PCR instruments that laboratories already own, with no closed platform to buy into. CircuLOK MDR‑TB covers rifampicin and isoniazid resistance, and CircuLOK pre‑XDR‑TB adds fluoroquinolone resistance. Laboratories can choose the resistance coverage that fits their patients and their budget, and expand it as their needs grow. For high-volume TB screening, CircuLOK TBDx, a lyophilised multiplex qPCR test with four gene targets, will shortly be available for research use, with full regulatory approval expected in 2027. Positive samples are reflexed to resistance testing.
Looking ahead, we are extending PLi‑RCA to the drugs in the WHO-recommended BPaLM regimen, with tests for bedaquiline, linezolid and pretomanid in development. Our aim is for drug-susceptibility testing to keep pace with the regimens now being rolled out, so that clinically actionable resistance information is available wherever TB is diagnosed.
A shared responsibility
The editorial ends by noting that the journal’s readers, the clinicians, programme managers and laboratory professionals of the TB community, will decide whether the next decade looks different from the last. We agree, and we see diagnostic companies as part of that community too. Ending TB will take more than more tests. It will take the right tests, in the right places, at the right time.
Learn more about the CircuLOK range.